Tag: GlobeNewswire

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK^® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

Clinical data for first combination of two T cell engagers in a solid tumor will be presented in a poster on Friday, November 6, and an oral presentation on November 7

(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, October 29, 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will present data from its Phase 1/2 trial evaluating brenetafusp alone and in combination with KIMMTRAK in HLA-A*02:01-positive patients with metastatic uveal melanoma, in a poster and oral session at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

The poster and oral presentations will include additional safety and efficacy data. The Company will issue a release on Friday, November 6, at 12:00 p.m. ET / 5:00 p.m. UK time when the poster session starts.

Presentation details

Title: Phase 1 evaluation of brenetafusp alone and in combination with tebentafusp in metastatic uveal melanoma (Abstract number: 1177)
Poster session: Poster Hall
Date and Time: Friday, November 6, 2026, 10:00 a.m. MST / 12:00 p.m. EST

Clinical oral abstract session: Session 2
Date and Time: Saturday, November 7, 2026, 1:45 p.m. MST / 3:45 p.m. EST

###

About ImmTAC^® molecules for cancer

Immunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognize and kill cancer cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on demonstrated T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of mutational burden or immune infiltration, tumors that are characterized as immune “cold” or having low mutation burden.

About the IMC-F106C-101 Phase 1/2 trial

IMC-F106C-101 is a first-in-human, Phase 1/2 dose escalation trial in patients with multiple solid tumors, including non-small cell lung and ovarian cancers, as well as uveal melanoma, evaluating brenetafusp both as monotherapy and in combination arms with standards-of-care. The Phase 1 dose escalation portion of the trial was designed to determine the maximum tolerated dose (MTD), as well as to evaluate the safety, preliminary anti-tumor activity and pharmacokinetics of IMC-F106C (brenetafusp) both as monotherapy and in combination with standards-of-care. Brenetafusp is a bispecific protein built on Immunocore’s ImmTAC technology, and the Company’s first molecule to target the PRAME antigen.

About KIMMTRAK

KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.

IMPORTANT SAFETY INFORMATION

Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated. Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK, with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending on persistence and severity of CRS.

Skin Reactions

Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.

Elevated Liver Enzymes

Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.

Embryo-Fetal Toxicity

KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during treatment with KIMMTRAK and 1 week after the last dose.

The most common adverse reactions (≥30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting. The most common (≥50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate.

For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS).

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in 39 countries, including the United States, European Union, Canada, Australia, and the United Kingdom.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “aim”, “continue”, “target” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the data from the Phase 1/2 trial evaluating brenetafusp alone and in combination with KIMMTRAK. Any forward-looking statements are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. These and other risks and uncertainties are described in greater detail in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 25, 2026, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.

Contact Information

Immunocore
Sébastien Desprez, Vice President, Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore

Ryan Baker, Vice President, Investor Relations
T: +1 (215) 384-4781
E: ryan.baker@immunocore.com

NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that a late-breaking abstract from its phase 2 PrTK05 clinical trial evaluating aglatimagene besadenovec (aglatimagene) in localized prostate cancer has been accepted for poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.

The presentation will feature longitudinal immune-profiling findings from PrTK05 (NCT07332000), together with biodistribution and viral shedding data, providing additional insights into the biological activity and characterization of aglatimagene in patients with localized intermediate-risk prostate cancer.

The poster presentation details are as follows:

Title: Longitudinal immune profiling in the PrTK05 trial of aglatimagene besadenovec plus valacyclovir with radiation therapy for localized intermediate-risk prostate cancer

Presenter: Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics

Abstract Number: 1172

Session Date: Saturday, November 7, 2026

Location: Phoenix Convention Center – North Building – Lower Level – Exhibition Halls 4, 5 and 6

About aglatimagene besadenovec

Aglatimagene besadenovec (aglatimagene), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) with results published in the Journal for ImmunoTherapy of Cancer, and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability profile to date, supporting the potential for use with standard of care, when indicated. Aglatimagene is currently not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any use.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene) is the lead product candidate from the adenovirus platform and is currently in an ongoing phase 3 clinical trial in NSCLC. Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in rHGG. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s nonclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com

CARLSBAD, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in and meet with investors at the following investor conferences:

Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum – New York, NY

Date: November 11, 2026

Panel: Innovative Diagnostics for Attractive Immunology Applications at 10:30am ET

Craig-Hallum’s Alpha Select Conference – New York, NY

Date: November 17, 2026

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a specialized diagnostics company with an autoimmune platform that empowers physicians to make more confident decisions, earlier. Its flagship test, AVISE® CTD, provides diagnostic clarity in complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease. Based in San Diego County, California, Exagen operates a CLIA-certified, CAP-accredited rheumatology laboratory delivering precise, timely results to physicians and partners across healthcare and biopharma. Through ongoing research and innovation, Exagen is committed to advancing care for autoimmune disease.  

For more information, visit Exagen.com or follow Exagen on LinkedIn.

Investors:
Tina Jacobsen, CFA
IR@exagen.com

Spotlights ibex’s Industry-leading Growth and Culture in the Region

WASHINGTON, Oct. 29, 2026 (GLOBE NEWSWIRE) — ibex (NASDAQ: IBEX), a global leader in outsourced business services and AI-powered customer experience solutions, was recognized as Frost & Sullivan’s 2026 Central America and the Caribbean Customer Experience Management Services Company of the Year. This reflects ibex’s outstanding performance, innovative AI-enabled solutions, and people-first leadership philosophy across its global footprint.

The report also acknowledged ibex’s significant growth in Central America and the Caribbean over the past seven years, including revenue growth of over 150% from 2018 to 2025.

“ibex’s continued innovation, substantial growth in Central America and the Caribbean region, and its highly rated client engagements make it the clear choice for CX Company of the Year,” said Sebastian Menutti, industry director at Frost & Sullivan. “With its leadership position in deploying AI-powered solutions, including AI Agents at scale, ibex has firmly established itself as the benchmark for CX delivery and execution in this region.”

“This recognition belongs to our teams across Central America and the Caribbean who deliver exceptional experiences for our customers every day,” said Bob Dechant, CEO of ibex. “It’s a testament to our growth and confirms what we’ve always believed: the companies that will win in customer experience are those that seamlessly combine the power of AI with human connection across the end-to-end customer journey.”

Frost & Sullivan’s Company of the Year recognition is powered by its Best Practices Criteria: a rigorous analytical process that involves a detailed evaluation across two dimensions for each nominated company. ibex was measured by Visionary Innovation & Performance and Customer Impact, excelling in both categories.

“The Central America and Caribbean region is a highly competitive talent market for customer service professionals, and our award-winning culture and employee development and growth opportunities help differentiate ibex from the pack,” said David Afdahl, Chief Operating Officer at ibex. “We’re proud of our consistent growth and industry-best employee Net Promoter Score of 82 and delighted to be recognized as the CX leader in this key region.”

With growing operations in Nicaragua, Honduras, and Jamaica, ibex continues to strengthen its position as the business process outsourcing leader and employer of choice in the region. ibex was also recently ranked in the Top 10 Best Places to Work for Service Professionals in the Caribbean and Central America by Great Place to Work^®, and remains committed to investing in its people, driving innovation, and creating meaningful opportunities for professional growth.

About ibex

ibex is a global leader in outsourced business services and AI-powered customer experience solutions, enabling the world’s best brands to deliver truly differentiated experiences for their customers. Leveraging a global team of more than 40,000 human CX experts – powered by the best AI technology, decades of CX innovation, and deep business insights – ibex engineers seamless, end-to-end customer journeys from AI agents to human agents at scale across retail, e-commerce, healthcare, fintech, utilities, technology, logistics, and more. Discover more at ibex.co and connect with us on LinkedIn.

Media Contact
Dan Burris
ibex
Daniel.Burris@ibex.co

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99bb7ba1-0f73-4f22-af62-7e5790e4e745

Oral presentation: November 20, 2026 at 15:00 CET

REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced the acceptance of an abstract on IM1240, the lead tri-specific antibody from its CAPTN-3 platform, for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held in Barcelona, Spain, on November 18-20, 2026.

Data evaluating IM1240 in treatment-resistant human tumor models, including its multi-arm mechanism of action and the contribution of NKG2A engagement, as well as pharmacokinetic and safety evaluation of CAPTN-3’s conditional CD3 masking approach, will be presented in a plenary session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai.

“We are pleased that our IM1240 abstract has been selected for a plenary session oral presentation at the EORTC-NCI-AACR Symposium,” said Isaac Israel, Interim Chief Executive Officer of Purple Biotech. “We are excited with the progress made in our latest work on the CAPTN-3 platform and its lead candidate IM1240 and we look forward to completing our IND-enabling work and, subject to regulatory clearance, initiating our planned first-in-human clinical study for IM1240 in 2027.”

Presentation:

Title: Conditionally activated NKG2A-engaging tri-specific antibody remodels IO-resistant human tumor microenvironments with improved tumor killing and pharmacologic safety
Session Title: Plenary Session 7: Proffered Papers
Abstract Number: ENA26-0137
Presenter: Amir Horowitz, Ph.D., Icahn School of Medicine at Mount Sinai
Date and Time: Friday, November 20, 2026, at 15:00 CET

The presentation is planned to be available on the Purple Biotech website following the presentation at the symposium.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. The Company is focused on advancing CAPTN-3 – a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells. Capping technology confines immune activation to the tumor microenvironment, significantly expanding the therapeutic window compared to conventional T-cell engagers. The platform’s lead candidate, IM1240, is advancing toward the clinic, and its second candidate, IM1305, is in preclinical development. The Company is headquartered in Rehovot, Israel. For additional information about the Company, please visit: https://purple-biotech.com.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for CAPTN-3; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; our ability to raise additional capital on acceptable terms, or at all, to fund our research and development activities, including preclinical and clinical studies; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2025 as such factors may be updated from time to time in our other filings with the U.S. Securities and Exchange Commission (“SEC”), including our cautionary discussion of risks and uncertainties under “Risk Factors” in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date on which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website, https://www.sec.gov.

CONTACTS:

Company Contact:
IR@purple-biotech.com

FAIRFAX, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) — WidePoint Corporation (NYSE American: WYY), a leading provider of Secure Mobility Management and Managed Services Solutions, will hold a conference call on Thursday, November 12, 2026, at 4:30 p.m. Eastern Time to discuss its financial results for the third quarter ended September 30, 2026. Financial results will be issued in a press release prior to the call.

WidePoint’s management will host the conference call, followed by a question and answer period.

Date: Thursday, November 12, 2026
Time: 4:30 p.m. ET (1:30 p.m. PT)
U.S. dial-in number: 888-506-0062
International number: 973-528-0011
Access Code: 633294

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at (949) 574-3860.

The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website. A replay of the conference call will be available after 7:30 p.m. ET on the same day through Thursday, November 26, 2026.

Toll-free replay number: 877-481-4010
International replay number: 919-882-2331
Replay ID: 54625

About WidePoint
WidePoint Corporation (NYSE American: WYY) is a leading technology Managed Solution Provider (MSP) dedicated to securing and protecting the mobile workforce and enterprise landscape. WidePoint is recognized for pioneering technology solutions that include Identity & Access Management (IAM), Mobility Managed Services (MMS), Telecom Management, Information Technology as a Service, Cloud Security, and Analytics & Billing as a Service (ABaaS). To learn more, visit https://www.widepoint.com. 

WidePoint Investor Relations:
Gateway Group, Inc.
Matt Glover or John Yi
949-574-3860
WYY@gateway-grp.com

Nonclinical studies demonstrated reductions in two key measures of neuropathic pain

Ongoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13’s potential to address multiple cancer-related symptoms

SOLANA BEACH, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions, today announced that it will present data demonstrating the potential of ART27.13 to treat chemotherapy-induced neuropathic pain at the IASP 2026 World Congress on Pain, taking place October 26–30, 2026, in Bangkok, Thailand.

Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, will deliver a presentation today entitled “88: Effects of ART27.13 in a Preclinical Model of Paclitaxel-Induced Peripheral Neuropathy.”

ART27.13, a once-daily oral, peripherally selective CB1 and CB2 receptor agonist, is currently in Phase 2 clinical development for cancer-related anorexia and weight loss. The findings highlight its potential to address chemotherapy-induced neuropathic pain, expanding its possible applications in cancer supportive care.

ART27.13 – Exploring New Potential in Chemotherapy-Induced Neuropathic Pain

• Significant unmet need: Chemotherapy-induced peripheral neuropathy affects approximately 60% to 80% of patients receiving paclitaxel, highlighting the need for effective pain management alternatives.
• Encouraging pain data: In a nonclinical model of paclitaxel-induced peripheral neuropathy, repeated dosing with ART27.13 reduced sensitivity to touch (mechanical allodynia) and heat (thermal hyperalgesia) in both male and female animals.
• Ongoing clinical evaluation: Artelo has incorporated multiple pain endpoints into its ongoing Phase 2 Cancer Appetite Recovery Study (CAReS) to assess whether the analgesic effects observed in nonclinical studies translate to patients with cancer.
• Broader therapeutic potential: ART27.13 may offer a single, once-daily oral treatment addressing multiple cancer-related symptoms, including appetite loss, weight loss and neuropathic pain.

“Cancer patients frequently experience multiple debilitating symptoms, including appetite loss, weight loss and neuropathic pain, yet treatment options remain limited,” said Professor O’Sullivan. “Our nonclinical findings demonstrate ART27.13’s potential to reduce chemotherapy-induced neuropathic pain, complementing the encouraging weight gain and activity improvements observed from our Phase 2 CAReS trial’s interim analysis. Importantly, the trial already includes pain endpoints, providing an opportunity once CAReS is completed to evaluate whether ART27.13 could address multiple cancer-related symptoms through a single, once-daily oral therapy.”

Organized by the International Association for the Study of Pain (IASP), the World Congress on Pain is the largest global gathering of pain professionals, bringing together thousands of scientists, clinicians and healthcare providers from around the world.

About ART27.13

Initially developed by AstraZeneca plc, ART27.13 is a dual cannabinoid agonist that has been evaluated in six clinical studies and two ongoing clinical trials with nearly 300 participants. It is being developed as a once-daily oral agent that selectively targets peripheral CB1 and CB2 receptors, enabling systemic metabolic effects while minimizing central nervous system-mediated toxicity.

Artelo is conducting a Phase 2 trial, the Cancer Appetite Recovery Study (CAReS), evaluating ART27.13 as a supportive care therapy for cancer patients with anorexia and weight loss. Patients had to have lost at least 5% of body weight to enroll. In interim data, those titrated to the highest dose (1300 µg) gained an average of 6% of body weight over 12 weeks, while patients on placebo lost an additional ~5%. There is currently no FDA-approved treatment for cancer anorexia cachexia syndrome. ART27.13 is also being evaluated in DREAM, a Phase 2 study in people with glaucoma investigating whether oral daily treatment can lower intraocular pressure.

About Artelo Biosciences

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in obesity, anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth or partnering opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including but not limited to: our ability to raise additional capital in the future; the inherent uncertainties of preclinical and clinical research, including the possibility that results observed in nonclinical animal models may not be predictive of, or replicated in, human clinical trials; the uncertainty of patent protection and the potential for intellectual property challenges; the highly competitive nature of the pharmaceutical industry; the risk that third-party market projections may not materialize or that the Company may not be able to participate in projected market opportunities; the timing, content and availability of the Company’s presentations at the IASP 2026 World Congress on Pain; and our ability to enter into partnering or licensing arrangements on acceptable terms, or at all. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email: ARTL@crescendo-ir.com

New Global Insights Report finds accuracy and effectiveness among marketers’ top priorities when evaluating AI solutions

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — DoubleVerify (“DV”) (NYSE: DV), the leading software platform to verify media quality, optimize ad performance and prove campaign outcomes, today released new findings from its 2026 Global Insights Report, Beyond the Hype: The Real State of AI in Digital Advertising, revealing that 97% of marketers plan to use AI across some aspects of media planning, buying and optimization in 2026. However, the findings reveal that broad plans to use AI have yet to translate into equally widespread adoption across individual advertising workflows. Drawing on a global survey of 2,020 marketers and additional DV data, the report examines where AI is gaining traction, as well as the priorities and concerns shaping marketers’ evaluation of AI solutions.

“AI is becoming a part of how nearly every marketer plans and buys media, but when you look at adoption across individual workflows, the picture is more nuanced,” said Mark Zagorski, CEO, DV. “Marketers are increasingly embracing AI, but there’s still considerable opportunity to integrate it more deeply into each step of how campaigns are planned, bought and optimized.”

Key report findings include:

• More marketers are using AI to develop media briefs: AI adoption for summarizing media briefs increased from 28% in 2024 to 37% in 2025, with usage expected to reach 40% in 2026.
• AI is gaining ground in campaign activation and bidding: In 2025, 35% of marketers used AI to activate campaigns, up from 31% in 2024, while 29% used it to optimize bidding, up from 24%. Usage is expected to reach 40% and 34%, respectively, in 2026.
• AI adoption for mid-flight optimization is accelerating: The percentage of marketers using AI to optimize campaigns mid-flight (adjusting campaigns while live) increased by 10 percentage points, from 21% in 2024 to 31% in 2025, with usage expected to reach 36% in 2026.

Despite uneven adoption across individual workflows, AI-powered bidding is delivering promising results: 98% of marketers using these solutions reported performance improvements, according to DV’s research.

Accuracy and Effectiveness Lead Marketers’ AI Priorities

As AI takes on a greater role in advertising operations, marketers are placing significant emphasis on the quality, reliability and value of the solutions they adopt. When evaluating AI optimization offerings, marketers prioritize:

• Accuracy and effectiveness of AI recommendations and optimization (35%), the most frequently cited consideration.
• Data privacy and security compliance (29%), reflecting the importance of protecting sensitive information as AI becomes more integrated into advertising operations.
• Cost and return on investment (29%), highlighting the need to demonstrate tangible business value from AI investments.

“Today’s AI optimization solutions are already helping marketers make smarter decisions and improve campaign performance,” added Zagorski. “As these capabilities advance, we expect AI agents to take on a greater role in managing campaign optimization on behalf of advertisers. That creates significant opportunity, but it also raises the stakes for accuracy, transparency and measurable performance. Marketers need to trust not only the recommendations AI makes, but also the actions it takes.”

DV helps advertisers automate and optimize campaign performance through DV Scibids AI^™, which uses first-party data and trusted third-party measurement inputs to generate custom bidding algorithms aligned with campaign KPIs. The technology helps improve campaign outcomes while reducing the need for manual optimization. DV Scibids AI is part of DV’s Media AdVantage Platform (DV MAP^™), which brings together media verification, AI-powered optimization and outcomes measurement to help advertisers improve media effectiveness and return on ad spend.

The full 2026 Global Insights Report: Beyond the Hype: The Real State of AI in Digital Advertising is available for download here.

About DV
DoubleVerify (“DV”) (NYSE: DV) is the industry’s leading media effectiveness platform that leverages AI to drive superior outcomes for global brands. By creating more effective, transparent ad transactions, DV strengthens the digital advertising ecosystem, ensuring a fair value exchange between buyers and sellers of digital media. For more information about DV, visit http://www.doubleverify.com.

Chris Harihar 
646-535-9475 
chris@crenshawcomm.com 

SurgePays expands GrowthLine into the rural broadband market, with iPMobile expected to bring more than 15 providers onto the platform over the next 12 months

GrowthLine partnership with iPMobile expected to serve hundreds of thousands of customers over time

BARTLETT, Tenn., Oct. 29, 2026 (GLOBE NEWSWIRE) — SurgePays, Inc. (NASDAQ: SURG) (“SurgePays” or the “Company”), a fintech company that launches and runs wireless brands, today announced a definitive agreement with IP Mobile, LLC (“iPMobile”) to bring rural broadband providers onto GrowthLine by SurgePays. The partnership enables participating broadband providers to offer wireless service to their existing customers under their own brands, with SurgePays providing the complete wireless operation.

iPMobile will serve as SurgePays’ exclusive rural broadband sales channel partner, recruiting providers and securing agreements for their branded wireless offerings. SurgePays will serve as iPMobile’s exclusive wireless platform partner, providing carrier access, technology, activation, billing and payments, customer care, compliance and daily operations through its GrowthLine platform.

“We intend to move aggressively and with a custom-tailored solution for smaller size wireless internet service providers (WISP) to large fiber providers and everyone in between. We are not just connecting to 5G services, but providing a full white label, white glove service led by SurgePays’ development and technology team and a full go to market plan and strategy supported by iPMobile. We expect to bring more than 15 rural broadband brands onto GrowthLine over the next 12 months and build this partnership into a wireless business serving hundreds of thousands of customers,” said Brett Wantland, Vice President of iPMobile. “These providers have already earned a place in their customers’ homes. Our opportunity is to help them win the wireless business, too. We believe SurgePays’ GrowthLine platform is the perfect solution for any broadband company, big or small. The wireless industry is changing, and broadband companies want to stay ahead of the curve, protect their existing base, and serve more of their needs. With our combined 60+ years in telecom, we know this isn’t as easy as getting connected. Our broadband providers need a partner that can guide them through the entire process, from start to finish and beyond. We see this as a major growth channel to deliver that solution while offering a seamless and integrated billing platform.”

“With the launch of GrowthLine, we expanded how SurgePays grows, offering partners access to our entire infrastructure, including 24/7 live support. We believe we have built not only the most innovative platform but also the only platform that encompasses every aspect of a wireless operation. For partners seeking to launch their own wireless brands, we have made the process fast, simple, and profitable. This partnership with iPMobile further validates that approach and gives us a direct pipeline to rural broadband providers that have already built customer relationships. Each provider iPMobile brings onto GrowthLine can sell wireless service to its existing customers, adding subscribers to infrastructure we have already built. That operating leverage is how we plan to build value for the Company,” said Brian Cox, Chief Executive Officer of SurgePays.

“Rural broadband companies already have the customer relationships. This partnership gives them another service to sell to those customers, a new source of recurring revenue, and a way to defend those customers against emerging companies that offer broadband and wireless together,” said Allison Seyler, Vice President of Sales at SurgePays. “iPMobile brings the sales channel, the broadband companies bring their brands and customers, and GrowthLine provides the wireless operation.”

The program lets broadband providers expand their service offerings while keeping their own customer-facing brands. Each participating provider will receive a negotiated share of margin after direct costs. iPMobile will manage provider recruitment and commercial relationships, while SurgePays operates the wireless service and back office.

About SurgePays, Inc.

SurgePays, Inc. (NASDAQ: SURG) is a fintech company that launches and runs wireless brands. Through its GrowthLine platform, SurgePays provides partners with carrier access, technology, payments, customer care, compliance and daily operations from platforms it developed and an operations center and NOC it runs. The Company also owns LinkUp Mobile, its own prepaid wireless brand, and operates SurgePays POS, which handles retail sales and payments for wireless companies at neighborhood stores. SurgePays brings affordable wireless service and prepaid financial products to consumers through partners and neighborhood stores. For more information, please visit www.surgepays.com.

About iPMobile

iPMobile helps rural and regional Internet Service Providers launch and grow their own wireless offerings, from carrier connectivity and devices to strategy, marketing, operations, and ongoing optimization. For more information, please visit www.ipmobile.ai.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth of the iPMobile partnership, the expectation that more than 15 rural broadband brands will join GrowthLine over the next 12 months, the expectation that the partnership will serve hundreds of thousands of wireless customers over time, the timing of partner brand launches, customer adoption, recurring revenue, margins, operating leverage and the future performance of the Company. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, and actual results could differ materially from those expressed or implied. The brand and customer expectations described in this release are not commitments from broadband providers or customers, and there can be no assurance that these expectations will be achieved or that partner brands will launch on anticipated timelines. Factors that could cause actual results to differ materially include, among others, the ability to recruit and onboard broadband providers, customer conversion and retention, the Company’s dependence on carrier and payment relationships, partner performance, regulatory developments affecting wireless and payment services, competition, and the risks and uncertainties described in the filings of the Company with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. SurgePays undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Investor Relations Contact

SurgePays, Inc.
ir@surgepays.com

• Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer
• Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach

BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer’s (“SITC”) Annual Meeting. The meeting will take place November 4-8, 2026 in Phoenix, Arizona.

Presentation Details:

Keynote/Plenary Session

Title: Updates on Clinical Results from the AMPLIFY-7P Study of a Lymph Node-Targeted KRAS Vaccine
Presenter: Darrell J. Irvine, PhD, The Scripps Research Institute
Session Number/Name: 103: Thomas Waldmann Memorial Plenary Session: Cancer Vaccines, Current and Future
Presentation Date/Time: Friday, November 6, 2026, at 10:04 am MT
Location: Phoenix Convention Center – North Building – 300 Level – Halls BC

Late-Breaking Abstract Poster Presentation

Title: Seven valent mKRAS lymph node targeted amphiphile vaccine drives mKRAS-specific T cell responses that correlate with improved clinical outcomes in the AMPLIFY-7P randomized phase 2 trial
Presenter: Christopher M. Haqq
Abstract Number: 1186
Session Date/Time: Saturday, November 7, 2026, 12:30-1:30 pm MT and 6:40-8:10 pm MT
Location: Phoenix Convention Center – North Building -Lower Level – Exhibition Halls 4-6

Poster Presentation

Title: Direct intratumoral delivery of amphiphilic immunomodulators induces durable anti-tumor efficacy
Presenter: Martin Steinbuck
Abstract Number: 824
Session Date/Time: Saturday, November 7, 2026, at 12:30-1:30pm MT and 6:40-8:10pm MT
Location: Phoenix Convention Center – North Building – Lower Level – Exhibition Halls 4-6

About the AMPLIFY-7P Phase 2 Study

AMPLIFY-7P Phase 2 is a randomized study evaluating camupepimut (ELI-002 7P) versus observation in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma following completion of standard locoregional therapy. The study enrolled 144 patients across 24 U.S. clinical sites.

About camupepimut (ELI-002 7P)

Camupepimut is an investigational, off-the-shelf immunotherapy designed to generate immune responses against seven of the most common KRAS mutations. Camupepimut utilizes Elicio’s proprietary Amphiphile (“AMP”) technology to target mutant KRAS peptide antigens and an immune-stimulatory adjuvant directly to the lymph nodes, where adaptive immune responses are orchestrated.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies.

Elicio’s AMP technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s camupepimut lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors.

Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid, commercial-scale manufacturing and rapid availability of drug to patients, especially in neoadjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches.

Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively.

For more information, please visit www.elicio.com.

Cautionary Note on Forward-Looking Statements

Certain statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA.

These include statements regarding the timing and content of Elicio’s presentation at SITC 2026 Annual Meeting; the clinical activity, therapeutic potential and potential benefits of camupepimut (ELI-002 7P); the interpretation and potential implications of results and analyses from Elicio’s preclinical studies; the interpretation and potential implications of results and analyses from Elicio’s AMPLIFY-7P study, including the observation that mKRAS-specific T cell responses correlate with improved clinical outcomes; Elicio’s planned clinical programs, including planned clinical trials; the potential of Elicio’s product candidates and platform; the potential for pre-specified analyses to further characterize the clinical activity of camupepimut (ELI-002 7P); the potential benefits and effectiveness of off-the-shelf immunotherapy approaches; the potential participation and presentation at upcoming conferences and medical meetings; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them.

No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law.

Elicio uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.

Such forward-looking statements are based on Elicio’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio’s plans to develop and commercialize its product candidates, including camupepimut; the timing of initiation of Elicio’s planned clinical trials; the timing of the availability and presentation of data from Elicio’s clinical trials; the design and timing of future clinical trials; the timing of any planned investigational new drug application or new drug application; Elicio’s plans to research, develop and commercialize its current and future product candidates; and Elicio’s estimates regarding future revenue, expenses, capital requirements and need for additional financing. New factors emerge from time to time, and it is not possible for Elicio to predict all such factors, nor can Elicio assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

These risks are more fully discussed under the heading “Risk Factors” in Elicio’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, as amended on April 29, 2026, Elicio’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 11, 2026, and Elicio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 13, 2026, as updated by subsequent reports and other documents filed from time to time with the SEC.

Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.

Elicio Investor Relations Contact

Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com